---
title: "Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296262041.md"
description: "Cellectar BioSciences published a corporate presentation detailing its phospholipid drug conjugate oncology platform. The company outlined plans for a Phase 3 confirmatory study of iopofosine I-131 in Waldenström macroglobulinemia, targeting first patient enrollment in Q1 2027 and an accelerated approval filing in H1 2027 based on positive Phase 2b CLOVER-WaM data. The presentation also highlighted the expansion of its PDC pipeline, including CLR 125 for TNBC and CLR 225 for pancreatic cancer."
datetime: "2026-08-18T19:24:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296262041.md)
  - [en](https://longbridge.com/en/news/296262041.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296262041.md)
generator: "portal-rs"
---

# Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program

-   Cellectar outlined a Phase 3 confirmatory study for iopofosine I 131 in Waldenström macroglobulinemia, targeting first patient enrolled in 1Q27. \* Accelerated approval filing targeted for 1H27 using Phase 2b CLOVER-WaM data with Phase 3 initiation and progress. \* Phase 2b CLOVER-WaM showed statistically significant primary endpoint; evaluable population ORR 83.6%, MRR 61.8%, DCR 98.2%, VGPR/CR 14.5%. \* Median duration of response 533 days (17.8 months); median progression-free survival 406 days (13.5 months) at December 2025 cutoff. \* Presentation also highlighted PDC platform expansion, including CLR 125 in Phase 1b/2 TNBC and CLR 225 Actinium-225 pancreatic program listed as Phase 1a/b ready. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md)

## Related News & Research

- [Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/296502875.md)
- [CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials](https://longbridge.com/en/news/296262059.md)
- [Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | CLRB Stock News](https://longbridge.com/en/news/295789747.md)
- [Cellectar Biosciences Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/295806334.md)
- [Arctic Bioscience to webcast half-year results and operational update](https://longbridge.com/en/news/296448311.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**